AAPL 235.75 1.3455% MSFT 410.155 -0.3123% NVDA 130.825 -1.4872% GOOGL 183.46 -1.0037% GOOG 185.285 -0.9542% AMZN 230.915 -0.7927% META 724.9999 0.7224% AVGO 234.6 -0.1872% LLY 872.51 0.8682% TSLA 343.535 4.5769% TSM 206.27 -1.1833% V 351.22 0.1426% JPM 276.24 0.4546% UNH 530.45 -0.6499% NVO 81.515 -2.657% WMT 103.49 0.9954% LVMUY 144.14 1.0091% XOM 107.94 -2.4756% LVMHF 722.5 1.7606% MA 563.03 -0.2957%
AAPL 235.75 1.3455% MSFT 410.155 -0.3123% NVDA 130.825 -1.4872% GOOGL 183.46 -1.0037% GOOG 185.285 -0.9542% AMZN 230.915 -0.7927% META 724.9999 0.7224% AVGO 234.6 -0.1872% LLY 872.51 0.8682% TSLA 343.535 4.5769% TSM 206.27 -1.1833% V 351.22 0.1426% JPM 276.24 0.4546% UNH 530.45 -0.6499% NVO 81.515 -2.657% WMT 103.49 0.9954% LVMUY 144.14 1.0091% XOM 107.94 -2.4756% LVMHF 722.5 1.7606% MA 563.03 -0.2957%

Stocks under $1 Report

US and Canadian markets settled this week on a negative note, Two stocks to consider – TAL, FGEN

Jan 10, 2025

TAL:TSX
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (CA$)
FGEN:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Company Overview: PetroTal Corp. (TSX: TAL) is an oil and gas company. The company is engaged in the exploration, appraisal, and development of crude oil and natural gas in Peru, and South America. FibroGen, Inc. (NASDAQ: FGEN) incorporated on September 29, 1993, is a biopharmaceutical company focused on developing and commercializing innovative therapeutics targeting critical areas of cancer biology and anemia. The Report covers the Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendations on these two stocks. 

Global Markets Wrap-Up 

On January 08, 2025, the S&P 500 index settled at 5918.25 with a week till date loss of 0.96%; moreover, the tech-heavy NASDAQ composite declined by ~0.73% on a WTD basis and settled at 19478.88. While the Russell 2000 settled at 2238.96, reflecting a loss of ~1.30% on a WTD basis.

Considering the Canadian market, the benchmark S&P/TSX Venture Composite Index (TSX: ^JX) started the week on a negative note and continued the momentum. On January 09, 2025, the index closed at 615.08 with an overall week-to-date (WTD) loss of 1.32%. Industrials, consumer non-cyclicals, financials, basic materials, energy, consumer cyclicals, and technology were the leading sectors, while healthcare and real estate were the laggards on Thursday. 

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.